A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

Vaccine

Volumn 32, Issue 52, 2014, Pages 7098-7107

  van Dissel, Jaap T ^a   Joosten, Simone A ^a   Hoff, Søren T ^b   Soonawala, Darius ^a   Prins, Corine ^a   Hokey, David A ^c   O'Dee, Dawn M ^c   Graves, Andrew ^c   Thierry Carstensen, Birgit ^b   Andreasen, Lars V ^b   Ruhwald, Morten ^b   de Visser, Adriëtte W ^a   Agger, Else Marie ^b   Ottenhoff, Tom H M ^a   Kromann, Ingrid ^b   Andersen, Peter ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STATENS SERUM INSTITUT   (Denmark)

^c AERAS   (United States)

Author keywords

Adjuvant; Clinical trial; Immunogenicity; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOSOMAL ADJUVANT CAF01; UNCLASSIFIED DRUG; AG85B-ESAT-6 FUSION ANTIGEN; HYBRID PROTEIN; LIPOSOME;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE STIFFNESS; INJECTION SITE SWELLING; MALAISE; MALE; MUSCULOSKELETAL STIFFNESS; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRURITUS; RASH; RHINITIS; T LYMPHOCYTE; TH1 CELL; VACCINATION; ADOLESCENT; CLINICAL TRIAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOLOGIC MEMORY; LIPOSOMES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUBERCULOSIS VACCINES; YOUNG ADULT;

EID: 84915751154     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.036     Document Type: Article

References (34)

1. World Health Organization Global tuberculosis report. WHO report 2013, WHO, Geneva.
2. Hanekom W.A., Dockrell H.M., Ottenhoff T.H., Doherty T.M., Fletcher H., McShane H., et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 2008, 5(July (7)):e145.
3. Ottenhoff T.H., Kaufmann S.H. Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog 2012, 8(5). e1002607.
4. Pitt J.M., Blankley S., McShane H., O'Garra A. Vaccination against tuberculosis: how can we better BCG?. Microb Pathog 2013, 58(May):2-16.
5. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381(March (9871)):1021-1028.
6. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28(April (20)):3571-3581.
7. van Dissel J.T., Soonawala D., Joosten S.A., Prins C., Arend S.M., Bang P., et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011, 29(March (11)):2100-2109.
8. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005, 1718(December (1-2)):22-31.
9. Christensen D., Agger E.M., Andreasen L.V., Kirby D., Andersen P., Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 2009, 19(1):2-11.
10. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008, 3(9):e3116.
11. Lindenstrom T., Knudsen N.P., Agger E.M., Andersen P. Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1-IL-2-secreting central memory cells. J Immunol 2013, 190(June (12)):6311-6319.
12. Lindenstrom T., Woodworth J., Dietrich J., Aagaard C., Andersen P., Agger E.M. Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun 2012, 80(October (10)):3533-3544.
13. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17(February (2)):189-194.
14. Schoenen H., Bodendorfer B., Hitchens K., Manzanero S., Werninghaus K., Nimmerjahn F., et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010, 184(March (6)):2756-2760.
15. Ottenhoff T.H. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012, 20(September (9)):419-428.
16. Kamath A.T., Mastelic B., Christensen D., Rochat A.F., Agger E.M., Pinschewer D.D., et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J Immunol 2012, 188(May (10)):4828-4837.
17. Graves A., Padilla M., Hokey D.A. OMIP-022. Comprehensive assessment of antigen-specific human T cell functionality and memory by intracellular cytokine staining. Cytometry A 2014, 85A(May):576-579.
18. Britten C.M., Janetzki S., Butterfield L.H., Ferrari G., Gouttefangeas C., Huber C., et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012, 37(July (1)):1-2.
19. Smith S.G., Joosten S.A., Verscheure V., Pathan A.A., McShane H., Ottenhoff T.H., et al. Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS ONE 2009, 4(11):e7972.
20. Fomsgaard A., Karlsson I., Gram G., Schou C., Tang S., Bang P., et al. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 2011, 29(September (40)):7067-7074.
21. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(October (5)):488-496.
22. Walzl G., Ronacher K., Hanekom W., Scriba T.J., Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11(May (5)):343-354.
23. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(April (4)):247-258.
24. Montoya J., Solon J.A., Cunanan S.R., Acosta L., Bollaerts A., Moris P., et al. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013, 33(November (8)):1360-1375.
25. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182(June (12)):8047-8055.
26. Tameris M., Geldenhuys H., Luabeya A.K., Smit E., Hughes J.E., Vermaak S., et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS ONE 2014, 9(2):e87340.
27. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007, 37(November (11)):3089-3100.
28. Gallo E., Katzman S. Eur J Immunol 2012, 42(September (9)):2322-2328.
29. Vernacchio L., Bernstein H., Pelton S., Allen C., MacDonald K., Dunn J., et al. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 2002, 20(November (31-32)):3658-3667.
30. Richert L., Hue S., Hocini H., Raimbault M., Lacabaratz C., Surenaud M., et al. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS 2013, 27(June (9)):1421-1431.
31. Agger E.M., Cassidy J.P., Brady J., Korsholm K.S., Vingsbo-Lundberg C., Andersen P. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology 2008, 124(June (2)):175-185.
32. Doherty T.M., Dietrich J., Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin Biol Ther 2007, 7(October (10)):1539-1549.
33. McKee A.S., Munks M.W., MacLeod M.K., Fleenor C.J., van Rooijen N., Kappler J.W., et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183(October (7)):4403-4414.
34. Chee C.B., Sester M., Zhang W., Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology 2013, 18(February (2)):205-216.